Tarsus Pharmaceuticals Inc(TARS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:34 PM ET (Korea 10/31 05:34)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.08 | Insider Own | 5.38% | Shs Outstand | 49.3M | Perf Week | 9.75% |
| Market Cap | 3.69B | Forward P/E | 73.62 | EPS next Y | 149.47% | Insider Trans | -3.72% | Shs Float | 46.6M | Perf Month | -0.81% |
| Enterprise Value | 3.33B | PEG | - | EPS next Q | -1.46 | Inst Own | 95.22% | Short Float | 12.29% | Perf Quarter | 22.06% |
| Income | -0.05B | P/S | 6.09 | EPS this Y | -29.24% | Inst Trans | 2.77% | Short Ratio | 6.88 | Perf Half Y | 17.65% |
| Sales | 0.61B | P/B | 9.34 | EPS next 5Y | - | ROA | -8.4% | Short Interest | 5.73M | Perf YTD | -8.59% |
| Book/sh | 8.01 | P/C | 8.21 | EPS past 3/5Y | 14.26% -3.8% | ROE | -13.68% | 52W High | -18.22% ($91.53) | Perf Year | 8.54% |
| Cash/sh | 9.12 | P/FCF | 65.9 | Sales past 3/5Y | 159.54% - | ROIC | -10.67% | 52W Low | 38.89% ($53.89) | Perf 3Y | 430.1% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 53.58% | Gross Margin | 93.28% | Volatility(W/M) | 3.63% 4.38% | Perf 5Y | 169.63% |
| Dividend TTM | - | EV/Sales | 5.49 | Sales Y/Y TTM | 105.17% | Oper. Margin | -8% | ATR (14) | 3.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.17 | EPS Q/Q | 10.97% | Profit Margin | -7.67% | RSI (14) | 55.11 | Recom | 1.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.2 | Sales Q/Q | 69.41% | SMA20 | 4.15% ($71.87) | Beta | 0.33 | Target Price | $98.89 |
| Payout | - | Debt/Eq | 0.26 | Earnings | 2026/11/3 | SMA50 | -0.41% ($75.16) | Rel Volume | 0.71 | Prev Close | $74.2 |
| Employees | 370 | LT Debt/Eq | 0.26 | EPS/Sales Surpr. | -124.19% 2.51% | SMA200 | 10.43% ($67.78) | Avg Volume(3M) | 0.83M | Price | $74.85 |
| IPO | 2020/10/16 | Option/Short | Yes/Yes | Trades | 9275 | Volume | 594,998 | Change | 0.88% |
A US commercial-stage biopharmaceutical company focused on therapeutics for eye diseases. It develops and commercializes innovative new drugs in underserved ophthalmology areas that large pharmaceutical companies have overlooked, centered on a treatment for blepharitis caused by Demodex mites. Alongside the rapid expansion in prescriptions for its first commercial product, it is broadening its pipeline to include ocular injectables and infectious disease prevention.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded less than usual. That is 71% of its average volume.
Next earnings report: November 3
1 days to go.
TARS has a sound balance sheet but weak earning power
Of every $100 in sales, $8.00 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -29.2% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $609. Peers typically go for $1,560.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +169.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 95.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #63 of 597 in the industry
Based on market cap of $4B.
TNGX#62 Tango Therapeutics Inc $4B PER - TARS#63 Tarsus Pharmaceuticals Inc $4B PER - 
XENE#64 Xenon Pharmaceuticals Inc $4B PER - 
IRON#65 Disc Medicine Inc $4B PER - 
ACAD#66 Acadia Pharmaceuticals Inc $4B PER 9.3 
FAQ
What kind of company is TARS?
TARS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TARS?
The market cap of TARS is approximately $3.7B, ranking 1,599 within its sector.
What is the 52-week high and low for TARS?
TARS has recorded a 52-week high of $91.53 and a low of $53.89.
